Fig. 3
From: MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Tumor response for patients with measurable disease. a Best percent change in tumor size. b Mean: percentage change in tumor size from baseline by cycle
